MedTrace Logo

A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC

NCT01673386 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2020-10-27

Study results available
· View outcomes & findings →

Summary

Randomized, double-blind, 2-arm crossover study comparing tivozanib hydrochloride and sunitinib in subjects with metastatic RCC who have received no prior systemic therapy for Renal Cell Carcinoma (RCC).

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Tivozanib

DRUG

Sunitinib

Sponsors & Collaborators

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • AVEO Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Needle, MD · AVEO Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States
  • Belgium
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01673386 on ClinicalTrials.gov